On November 5, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA) (Press release, Carisma Therapeutics, NOV 5, 2024, View Source [SID1234647760]). The data will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," presents the first pre-clinical data on the development candidate targeting Glypican-3 ("GPC3"), a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cells in vivo using lipid nanoparticles ("LNP") to deliver mRNA encoding CARs. The data show that this in vivo CAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.
"Our data at SITC (Free SITC Whitepaper) this year highlights the groundbreaking potential of the in vivo CAR-M platform," said Steven Kelly, President and Chief Executive Officer of Carisma. "The pre-clinical results demonstrate robust anti-tumor activity and pave the way for an off-the-shelf therapy for hard-to-treat cancers like hepatocellular carcinoma. This data underscores the progress we’ve made, and we’re eager to advance this promising therapy into clinical development."
SITC Presentations Details:
Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma
Publication Number: 329
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
Title: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Publication Number: 659
Session Date & Time: Friday, Nov. 8, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
The poster presented at SITC (Free SITC Whitepaper) 2024 will be available online in the "Publications" section of Carisma’s website at View Source following the start of the poster session.